Project Grant HT94252310137

This Project Grant award of $558,182 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will support research to identify mechanisms of neurofilament regulation and turnover in amyotrophic lateral sclerosis (ALS). The primary objectives are to: 1) compare neurofilament species in ALS and control biofluids to identify ALS-specific neurofilament...

The National Institute of Neurological Disorders and Stroke (NINDS), through the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, awarded Cedars-Sinai Medical Center a $227,205 project grant. The grant funds a 5-year research project to (1) use advanced MRI techniques to identify pathological markers associated with upper motor neuron degeneration in the motor cortex of amyotrophic lateral sclerosis (ALS) patients, and (2)...

This federal Project Grant award of $704,431.23 from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to Meso Scale Diagnostics LLC, doing business as Meso Scale Discovery, supports the development of ultrasensitive plasma and cerebrospinal fluid immunoassays to enable clinical trials for amyotrophic lateral sclerosis (ALS). As a for-profit limited liability company specializing in assay development, laboratory testing, and related products for biomedical...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $320,143 to the Mayo Clinic to determine the diagnostic utility of plasma biomarkers and their relation to pathophysiology in atypical Alzheimer's disease (AD). The 2-year project will leverage existing blood samples, clinical data, and neuroimaging from 210 patients to: 1) assess the value of plasma biomarkers as diagnostic tools for atypical AD, and 2) evaluate plasma biomarkers as...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,499,212 Project Grant (CFDA 93.853) to Aquinnah Pharmaceuticals, Inc. to develop a novel oral brain-penetrant therapeutic for amyotrophic lateral sclerosis (ALS). The project aims to manufacture, conduct IND-enabling studies, and hold a Pre-IND meeting with the FDA for a new drug candidate designed to slow and potentially reverse the progression of ALS by reducing the accumulation of insoluble, aggregated TDP-43...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Trustees of Columbia University in the City of New York provides $452,375 to investigate the potential use of the APLP1 protein as an early biomarker for Alzheimer's disease in individuals with Down syndrome. The project aims to leverage recent findings linking endosomal trafficking defects to the early pathology of Alzheimer's disease, which is observed decades before classical...

This Cooperative Agreement award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) will fund a project titled "SCALABLE EXPANDED ACCESS WITH ANALYSIS OF NEUROFILAMENT AND OTHER BIOMARKERS FOR IBUDILAST IN ALS (SEA-NOBI-ALS)". The award, totaling $6,133,297, will provide 200 ALS patients with access to the experimental drug ibudilast for a 6-month period. The project aims to develop a network of ALS physicians,...

This Project Grant award of $532,381.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to investigate the molecular mechanisms underlying the role of the KIF5A gene variant KIF5ADE27 in the pathogenesis of amyotrophic lateral sclerosis (ALS). The key objectives are to determine the gain-of-function effects of KIF5ADE27 in...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will support research to investigate the effects of re-expressing embryonic motor neuron selector transcription factors ISL1 and LHX3 in postnatal motor neurons in mouse models of amyotrophic lateral sclerosis (ALS) and in induced pluripotent stem cell-derived ALS motor...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, is focused on developing peptide nucleic acid (PNA) oligomers to disrupt biomolecular condensates associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The award of $74,305 to Carnegie Mellon University aims to (1) fluorescently label RNAs...